<DOC>
	<DOCNO>NCT00220168</DOCNO>
	<brief_summary>The objective study assess efficacy toxicity 3 weekly regimen contain irinotecan combine capecitabine set relapsed refractory upper gastrointestinal tumour . Patients locally advance metastatic adenocarcinoma squamous cell carcinoma originate oesophagus , oesophagogastric junction stomach previously receive chemotherapy either fail respond relapse within 3 month initial response eligible treatment study . The response rate , failure-free survival overall survival treat patient evaluate . Toxicity quality life also monitor closely .</brief_summary>
	<brief_title>Phase II Trial Evaluating Irinotecan Capecitabine Relapsed/Refractory Upper GI Tumours</brief_title>
	<detailed_description />
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically proven adenocarcinoma squamous cell carcinoma oesophagus , OG junction stomach , amenable surgical resection . Bidimensionally measurable disease , unidimensional measurable disease assessable CT scanning , within previously irradiate area . Patients progressive disease previous chemotherapy treatment within three month stop treatment . At least one previous chemotherapy regimen , give within 3 month prior inclusion study . No previous exposure irinotecan . Adequate bone marrow function platelet &gt; 100 X 109/L ; WBC &gt; 3 X 109/L ; Neutrophils &gt; 1.5 X 109/L time study entry . Satisfactory renal function . Creatinine clearance ( measure Cockcroft Gault ) &gt; 50ml/min Cr &lt; 135 . Satisfactory liver function : In absence liver metastasis : Bilirubin &lt; 1.25N ( N=upper limit normal range ) Hepatic transaminases &lt; 2.5N Prothrombin time &lt; 1.5N In presence liver metastasis : Bilirubin &lt; 1.5N Hepatic transaminase &lt; 5N Prothrombin time &lt; 1.5N No uncontrolled medical condition No previous malignant disease except nonmelanotic skin cancer insitu carcinoma uterine cervix . ECOG performance status 0 , 1 2 . Predicted life expectancy &gt; 3 month . Adequate contraceptive precaution Informed write consent Medical psychiatric condition result inability patient give write consent . ECOG Performance status &gt; 2 Intracerebral metastasis meningeal carcinomatosis Unresolved bowel obstruction Creatinine clearance &lt; 50ml/min , Cr &gt; 135 Uncontrolled angina pectoris , heart failure ( New York heart classification 3 4 ) . Pregnancy/lactation Previous malignancy adequately treat basal cell carcinoma skin cervical carcinoma situ .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>